Abbott Laboratories (ABT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert B. Ford | Chairman of the Board, President & CEO | 4.73M | 6.64M | 1974 |
| Mr. Philip P. Boudreau | CFO & Senior VP of Finance | 1.14M | -- | 1973 |
| Mr. Hubert L. Allen | Executive VP, General Counsel & Secretary | 2M | -- | 1966 |
| Mr. Robert E. Funck Jr. | Executive Vice President of Finance | 2.18M | -- | 1961 |
| Mr. Daniel Gesua Sive Salvadori | Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | 1.76M | -- | 1979 |
| Ms. Lisa D. Earnhardt | Executive VP & Group President of Medical Devices | 1.73M | -- | 1970 |
| Ms. Sabina Ewing | Senior VP of Business & Technology Services and Chief Information Officer | -- | -- | 1974 |
| Erica L. Battaglia | VP and Chief Ethics & Compliance Officer | -- | -- | -- |
| Ms. Melissa Brotz | Vice President of Public Affairs & Corporate Marketing | -- | -- | -- |
| Mr. Christopher J. Scoggins | Senior Vice President of Commercial Operations, Marketing & Diabetes Care | -- | -- | 1970 |
Abbott Laboratories
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 114,000
Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Corporate Governance
Recent Events
- Apr 17, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 12, 2024Ex-Dividend Date
- Mar 15, 2024DEF 14A: Proxy StatementsSee Full Filing
- Feb 16, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 29, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 15, 2024
Dividend Date